Clinical Trial Update: Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating off-label ocrelizumab versus rituximab at onset of relapsing-remitting multiple sclerosis; currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)
• Rituxan (rituximab)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING